Neurocrine Biosciences, Inc.
NBIX
株式のランク
#1552
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the... Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.
株価
$140.48
時価総額
$14.28B
変化（1日）
2.56%
変化（1年）
-0.60%
国
US
取引 Neurocrine Biosciences, Inc. (NBIX)
カテゴリー
Healthcare
Neurocrine Biosciences, Inc.（NBIX）の利益
Jun 2026 時点の利益 TTM: $940.20M
Neurocrine Biosciences, Inc. の最新の財務報告によると、同社の現在の利益は $940.20M です。2024 年には $486.00M の利益を上げ、これは 2023 年の利益 $332.10M と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Neurocrine Biosciences, Inc. の利益の推移（2000 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $940.20M | 33.29% |
| 2025 | $705.40M | 45.14% |
| 2024 | $486.00M | 46.34% |
| 2023 | $332.10M | 55.26% |
| 2022 | $213.90M | 110.95% |
| 2021 | $101.40M | -4.97% |
| 2020 | $106.70M | 129.46% |
| 2019 | $46.50M | 112.90% |
| 2018 | $21.84M | -115.32% |
| 2017 | $-142.54M | 1.03% |
| 2016 | $-141.09M | 58.65% |
| 2015 | $-88.93M | 46.89% |
| 2014 | $-60.54M | 31.36% |
| 2013 | $-46.09M | -1,017.21% |
| 2012 | $5.03M | -86.63% |
| 2011 | $37.57M | -571.52% |
| 2010 | $-7.97M | -91.01% |
| 2009 | $-88.61M | 0.00% |
| 2008 | $-88.61M | -57.25% |
| 2007 | $-207.30M | 93.37% |
| 2006 | $-107.21M | 383.10% |
| 2005 | $-22.19M | -51.44% |
| 2004 | $-45.69M | 51.82% |
| 2003 | $-30.10M | -68.16% |
| 2002 | $-94.54M | 156.96% |
| 2001 | $-36.79M | 29.06% |
| 2000 | $-28.51M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $5.27B | 461.04% |
US
|
|
| $-3.09B | -428.33% |
US
|
|
| $-4.02B | -527.16% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 107.47% |
NL
|
